Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H24FN3O2 |
| Molecular Weight | 417.4754 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC2=C(NC=C2C3=CCN(CCCCN4C(=O)C5=C(C=CC=C5)C4=O)CC3)C=C1
InChI
InChIKey=NECJNLXOJRDELU-UHFFFAOYSA-N
InChI=1S/C25H24FN3O2/c26-18-7-8-23-21(15-18)22(16-27-23)17-9-13-28(14-10-17)11-3-4-12-29-24(30)19-5-1-2-6-20(19)25(29)31/h1-2,5-9,15-16,27H,3-4,10-14H2
| Molecular Formula | C25H24FN3O2 |
| Molecular Weight | 417.4754 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:24:12 GMT 2025
by
admin
on
Tue Apr 01 17:24:12 GMT 2025
|
| Record UNII |
69GK99VB9C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
264869-71-8
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY | |||
|
9888211
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY | |||
|
69GK99VB9C
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY | |||
|
300000041438
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
SLV 310 is a novel compound combining potent dopamine D 2
receptor antagonism with serotonin reuptake inhibition.
|
||
|
ACTIVE MOIETY |
The antipsychotic potency of 6b was demonstrated by the fact that 6b significantly disrupted avoidance behaviour14 in a conditioned avoidance response paradigm in three independent groups of trained rats (ED50=17.5 mg/kg, po, based on the HCl salt of 6b). It can be concluded that 6b is a promising novel antipsychotic indeed, combining strong dopamine D2-receptor antagonism with SRI effects in the same dose range.
|